[go: up one dir, main page]

MX9203346A - (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles. - Google Patents

(+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.

Info

Publication number
MX9203346A
MX9203346A MX9203346A MX9203346A MX9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A MX 9203346 A MX9203346 A MX 9203346A
Authority
MX
Mexico
Prior art keywords
sobenofuran
dimetilaminopropil
fluorfenil
carbonitrilo
dihidro
Prior art date
Application number
MX9203346A
Other languages
English (en)
Inventor
Klaus Peter Bogeso
Jens Kristian Perregaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10638616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX9203346A publication Critical patent/MX9203346A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Compounds (AREA)
MX9203346A 1988-06-14 1992-06-25 (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles. MX9203346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888814057A GB8814057D0 (en) 1988-06-14 1988-06-14 New enantiomers & their isolation
US07/363,589 US4943590A (en) 1988-06-14 1989-06-08 Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof

Publications (1)

Publication Number Publication Date
MX9203346A true MX9203346A (es) 1992-08-31

Family

ID=10638616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203346A MX9203346A (es) 1988-06-14 1992-06-25 (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.

Country Status (24)

Country Link
US (2) US4943590A (es)
EP (1) EP0347066B1 (es)
JP (2) JP3044253B2 (es)
AT (1) ATE119896T1 (es)
AU (1) AU623144B2 (es)
CA (2) CA1339452C (es)
CY (2) CY2081B1 (es)
DE (2) DE68921672T2 (es)
DK (2) DK259989A (es)
ES (1) ES2068891T4 (es)
FI (4) FI98627C (es)
GB (1) GB8814057D0 (es)
GR (1) GR3015889T3 (es)
HK (1) HK139596A (es)
HU (1) HU211460A9 (es)
IE (1) IE65734B1 (es)
IL (1) IL90465A (es)
LU (1) LU90999I2 (es)
MX (1) MX9203346A (es)
NL (1) NL300155I2 (es)
NO (2) NO172892C (es)
NZ (1) NZ229426A (es)
PT (1) PT90845B (es)
ZA (1) ZA894476B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
DE69224290T2 (de) * 1991-05-20 1998-07-09 Chisso Corp Optisch aktive trifluormilchsäurederivate und flüssigkristallzusammensetzungen
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
DE4439836C1 (de) * 1994-11-08 1996-06-05 Hoechst Ag cis-4-(2,2,3,3-Tetrafluorpropoxy)-zimtsäurenitril und trans-4-(2,2,3,3-Tetrafluorpropoxy)- zimtsäurenitril und ein Verfahren zu ihrer Herstellung
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
ES2189502T3 (es) * 1998-10-20 2003-07-01 Lundbeck & Co As H Metodo para la prevencion de citalopram.
KR100454008B1 (ko) 1998-12-23 2004-10-20 하. 룬트벡 아크티에 셀스카브 5-시아노프탈리드의 제조방법
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
SI1173431T2 (sl) * 1999-04-14 2009-12-31 Lundbeck & Co As H Postopek za pripravo citaloprama
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
HUP0200169A3 (en) * 1999-10-25 2002-11-28 Lundbeck & Co As H Method for the preparation of citalopram
TR200101874T1 (tr) * 1999-10-25 2002-02-21 H. Lundbeck A/S Sitalopram hazırlanması için yöntem
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
SI1246812T1 (en) * 1999-12-28 2004-08-31 H. Lundbeck A/S Method for the preparation of citalopram
CZ20022601A3 (cs) * 2000-01-14 2002-10-16 H. Lundbeck A/S Způsob výroby 5-kyanoftalidu
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
NL1017417C1 (nl) * 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
NZ521201A (en) * 2000-03-13 2004-02-27 H Method for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
TR200202195T2 (tr) * 2000-03-13 2002-12-23 H. Lundbeck A/S 5-Yer değiştirmiş 1-(4-florofenil)-1,3- dihidroizobenzofuran'ın adım adım alkillenmesi
PL360107A1 (en) 2000-03-14 2004-09-06 H.Lundbeck A/S Method for the preparation of citalopram
WO2001068632A1 (en) * 2000-03-16 2001-09-20 H. Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
HUP0302068A3 (en) * 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
IL144816A (en) 2000-08-18 2005-09-25 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
ATE222899T1 (de) * 2000-12-28 2002-09-15 Lundbeck & Co As H Verfahren zur herstellung von reinem citalopram
EP1355897A1 (en) * 2001-01-30 2003-10-29 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
HRP20030744A2 (en) * 2001-05-01 2005-06-30 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
EA006213B1 (ru) * 2001-07-31 2005-10-27 Х. Лундбекк А/С Кристаллическая композиция, содержащая эсциталопрам
PT1281707E (pt) * 2001-08-02 2005-04-29 Infosint Sa Processo para a preparacao de isobenzofuranos 5-substituidos
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
WO2003064617A2 (en) * 2002-01-30 2003-08-07 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
AR040970A1 (es) 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
CA2511143C (en) 2002-12-23 2011-06-28 H. Lundbeck A/S Preparation of racemic and/or s- or r-citalopram diols and their use for the preparation racemic and/or s- or r-citalopram
BR0317629A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Processo para a preparação de sal de adição de ácido e/ou base livre de diol racêmico e/ou de sal de adição de ácido e/ou base livre de r- ou s-diol, uso de sal de adição de ácido e/ou base livre de rs-diol e/ou de sal de adição de ácido e/ou base livre de s-diol e/ou de sal de adição de ácido e/ou base livre de r-diol, e, método para a preparação de sal de adição de ácido e/ou base livre de citalopram e/ou de sal de adição de ácido e/ou base livre de s-citalopram e/ou de sal de adição de ácido e/ou base livre de r-citalopram
CA2511142A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
CN1761659A (zh) * 2003-03-21 2006-04-19 H·隆德贝克有限公司 用于制备西酞普兰和依他普仑的中间体
WO2004085416A1 (en) * 2003-03-24 2004-10-07 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US7019153B2 (en) 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ES2228274B1 (es) * 2003-09-24 2006-06-01 Astur Pharma, S.A. Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram.
ATE293106T1 (de) * 2003-10-28 2005-04-15 Adorkem Technology Spa Verfahren zur herstellung von citalopram
US20050101666A1 (en) * 2003-11-07 2005-05-12 H. Lundbeck A/S Method of treating premenstrual dysphoric disorder with escitalopram
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
AU2003282383A1 (en) * 2003-11-20 2005-06-08 Natco Pharma Limited A process for the preparation of high purity escitalopram
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
EP1732514A1 (en) * 2004-03-05 2006-12-20 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
KR101166280B1 (ko) * 2004-08-23 2013-11-27 썬 파마 글로벌 에프제트이 시탈로프램 및 에난티오머의 제조 방법
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
WO2006025071A1 (en) * 2004-09-02 2006-03-09 Natco Pharma Limited A process for the preparation of escitalopram
ITMI20041872A1 (it) * 2004-10-01 2005-01-01 Adorkem Technology Spa Processo per la preparazione di citalopram e di scitalopram
EP1877394A1 (en) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Process for the preparation of escitalopram or its acid addition salts
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
EP1901714A2 (en) * 2005-05-20 2008-03-26 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP1987016A1 (en) * 2005-07-27 2008-11-05 Aurobindo Pharma Limited An improved process for the preparation of escitalopram
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
JP2009511606A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US8252336B2 (en) * 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
EP2078524B1 (en) 2006-10-27 2016-08-31 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
EP2134325A2 (en) * 2007-03-01 2009-12-23 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
ATE534639T1 (de) * 2007-04-23 2011-12-15 Synthon Bv Verfahren zur lösung von citalopram
JP2010527345A (ja) 2007-05-18 2010-08-12 シプラ・リミテッド エスシタロプラムの調製方法
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
KR101612563B1 (ko) * 2007-08-03 2016-04-14 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 조성물 및 도파민 수용체 리간드를 사용한 치료 방법
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
FI121570B (fi) 2007-09-11 2011-01-14 Lundbeck & Co As H Menetelmä essitalopraamin valmistamiseksi
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN101538257B (zh) * 2008-03-21 2012-10-17 浙江华海药业股份有限公司 一种制备西酞普兰和s-西酞普兰的方法
CN101265215B (zh) * 2008-04-18 2011-03-16 浙江奥托康制药集团股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20110230666A1 (en) * 2008-06-03 2011-09-22 Shodhana Laboratories Limited process for the separation of enantiomerically pure compounds
WO2010004575A2 (en) * 2008-06-16 2010-01-14 Shodhana Laboratories Limited Preparation of escitalopram, its salts and intermediates
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20100249438A1 (en) * 2009-03-30 2010-09-30 Vijaya Bhaskar Bolugoddu Preparation of escitalopram
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102757414B (zh) * 2011-04-25 2014-02-19 齐鲁制药有限公司 艾司西酞普兰草酸盐的制备方法
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
ITMI20120448A1 (it) 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
EP3219702B1 (en) * 2014-11-14 2021-05-05 Zhejiang Huahai Pharmaceuticals Co., Ltd. Method for resolution of citalopram intermediate 5-cyanogen diol
EP3309142B1 (en) 2015-06-09 2020-08-05 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing citalopram diol intermediate
CN107311968A (zh) * 2016-03-31 2017-11-03 广州市恒诺康医药科技有限公司 西酞普兰帕莫酸盐和其结晶形态及其制备方法和用途
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
CN111194312A (zh) 2017-10-09 2020-05-22 提瓦制药工业公司 依地普仑的新盐和固态形式
CN111217777A (zh) 2018-11-26 2020-06-02 上海奥博生物医药技术有限公司 一种高纯度艾司西酞普兰双羟萘酸盐新的制备工艺
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method

Also Published As

Publication number Publication date
USRE34712E (en) 1994-08-30
HK139596A (en) 1996-08-02
DK11593A (da) 1993-02-01
FI892823L (fi) 1989-12-15
ZA894476B (en) 1990-04-25
PT90845B (pt) 1994-11-30
HU211460A9 (en) 1995-11-28
PT90845A (pt) 1989-12-29
NO892447L (no) 1989-12-15
FI20000507A7 (fi) 2000-03-06
JPH0236177A (ja) 1990-02-06
NO2002014I2 (no) 2005-03-21
CA1339568C (en) 1997-12-02
CY2081B1 (en) 1998-10-16
DK259989D0 (da) 1989-05-29
GB8814057D0 (en) 1988-07-20
CY2007004I2 (el) 2009-11-04
DE68921672D1 (de) 1995-04-20
DK11593D0 (da) 1993-02-01
AU623144B2 (en) 1992-05-07
DE10399030I1 (de) 2004-01-08
GR3015889T3 (en) 1995-07-31
NO892447D0 (no) 1989-06-13
NO172892B (no) 1993-06-14
NL300155I2 (nl) 2005-09-01
ATE119896T1 (de) 1995-04-15
IE65734B1 (en) 1995-11-15
JP3044253B2 (ja) 2000-05-22
FI20041359L (fi) 2004-10-20
US4943590A (en) 1990-07-24
LU90999I2 (fr) 2003-03-17
FI91527B (fi) 1994-03-31
FI113762B (fi) 2004-06-15
NZ229426A (en) 1990-12-21
FI20000507L (fi) 2000-03-06
DK170280B1 (da) 1995-07-24
ES2068891T4 (es) 2012-02-07
FI20041359A7 (fi) 2004-10-20
FI98627C (fi) 1997-07-25
JP3038204B2 (ja) 2000-05-08
EP0347066B1 (en) 1995-03-15
DK259989A (da) 1989-12-15
NO172892C (no) 1993-09-22
FI941829A0 (fi) 1994-04-20
EP0347066A1 (en) 1989-12-20
IL90465A (en) 1995-01-24
FI892823A0 (fi) 1989-06-08
DE10399030I2 (de) 2004-08-12
IE891859L (en) 1989-12-14
CA1339452C (en) 1997-09-09
ES2068891T3 (es) 1995-05-01
AU623144C (en) 1990-01-04
NL300155I1 (nl) 2004-09-01
DE68921672T2 (de) 1995-07-27
AU3629589A (en) 1990-01-04
FI941829L (fi) 1994-04-20
JPH11292867A (ja) 1999-10-26
CY2007004I1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
MX9203346A (es) (+)-1-(3-dimetilaminopropil)-1-(4'-fluorfenil)-1,3-dihidro-sobenofuran -5-carbonitrilo y sus sales de adicion de acido no toxicas farmaceuticamente utiles.
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
ATE121066T1 (de) Verfahren zur herstellung von 6,12-dihydro-6- hydroxy-cannabidiol und dessen anwendung zur herstellung von trans-delta-9- tetrahydrocannabinol.
ATE132145T1 (de) Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate
DE69627166D1 (de) Verfahren zur herstellung von 2-chlor-5-chlomethyl-thiazol-derivaten
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
AU1027992A (en) Substituted 1,2,3,4-tetrahydrocyclopent(b)indoles, 1,2,3,3a,4,8a-hexahydrocyclopent(b)indoles and related compounds, intermediates and a process for the preparation thereof and their use as medicaments
ATE207482T1 (de) Verfahren zur herstellung von n2-arylsulfonyl-l- argininamiden
DE60107292D1 (de) Verfahren zur herstellung von (+)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE131155T1 (de) Verfahren zur herstellung von zwischenprodukten und zur synthese von n-(2-hydroxyethyl)-2- hydroxymethyl-3,4,5-trihydroxypiperidine.
ATE159246T1 (de) Verfahren zur herstellung von (s)-vinyl- und (s)- allenyl-gaba
IT8621359A1 (it) Processo per la sintesi di acidi carbossilici
ATE117676T1 (de) Verfahren zur herstellung von molluskiziden 2,4,5-tribrompyrrol-3-carbonitrilen.
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
DE68905799D1 (de) (+)1-((3,4,5-trimethoxy)benzyloxymethyl)-1-phenyl-n,n-dimethyl-n-propylamine, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
FI875602A0 (fi) Optiskt aktivt tetrahydro-2-furanonderivat saosom miksobicid.
ATE35679T1 (de) Verfahren zur herstellung von cis-3,3,5trimethylcyclohexyl-d,l-alpha-(3-pyridincarboxy - phenylacetat.
ATE27281T1 (de) Verfahren zur herstellung von oxanosin.